Abstract: The present invention relates to methods for deriving multipotent Isl1+ cells (i.e. methods for inducing a cell to enter a multipotent Isl1+ lineage), methods for differentiating Isl1+ cells to cardiac cells, cells obtainable by such methods, kits and compositions for carrying out the methods in accordance with the invention, and also medical applications and pharmaceutical compositions of said cells.

Abstract: The present invention relates to methods for deriving multipotent Isl1+ cells (i.e. methods for inducing a cell to enter a multipotent Isl1+ lineage), methods for differentiating Isl1+ cells to cardiac cells, cells obtainable by such methods, kits and compositions for carrying out the methods in accordance with the invention, and also medical applications and pharmaceutical compositions of said cells.

Abstract: The present invention relates to pharmaceutical compositions comprising mesenchymal cells (MSCs) and additional agents for blocking co-stimulation of the immune system. The compositions may optionally further comprise a therapeutic cell, a therapeutic tissue, and/or a therapeutic organ implant. Additionally, the instant invention pertains to medical uses of such compositions in immune-mediated diseases and disorders, in essentially all inflammatory and/or autoimmune diseases and conditions, and also in transplantation-related conditions.

Abstract: The present invention relates to, inter alia, methods for culturing mesenchymal stem cells (MSCs) (without the use of non-human serum components), MSCs and extracellular vesicles obtained from such culturing methods, having advantageous polypeptide profiles which are key for immuno-modulatory efficacy. Further, the present invention pertains to pharmaceutical compositions comprising such MSCs and/or extracellular vesicles, and medical treatment and prophylactic methods and medical uses of MSCs and/or extracellular vesicles in a variety of diseases, notably acute respiratory distress syndrome (ARDS), infant respiratory distress syndrome (IRDS), pulmonary hypertension (PH), and related diseases and ailments, such as organ failure.

Abstract: The present invention relates to methods for deriving multipotent Isl1+ cells (i.e. methods for inducing a cell to enter a multipotent Isl1+ lineage), methods for differentiating Isl1+ cells to cardiac cells, cells obtainable by such methods, kits and compositions for carrying out the methods in accordance with the invention, and also medical applications and pharmaceutical compositions of said cells.